Evaluation of the Efficacy and Tolerance of the Medical Device RL3020-DP0364 in Adult Population With Stable Mild Plaque Psoriasis, Dry Skin and Pruritus

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The product RL3020-DP0364 developed by Pierre Fabre Laboratories moisturizes durably and repairs dry or atopic skin, especially in the case of certain dermatoses (atopic dermatitis, ichthyosis, etc ...) and erythema induced by radiotherapy. Its unique formula treats the symptoms of dry skin by creating a protective film that prevents dehydration and helps protect the skin from external aggressions. Through this study, the efficacy of this medical device will be evaluated specifically in subjects presenting stable psoriasis, dry skin and pruritus with an application on the whole body (excluding the head).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Subject with stable mild plaque psoriasis covering ≤ 10% BSA (Body Surface Area; excluding the head\*)

• Subject whose plaque psoriasis has been diagnosed for at least 6 months before the inclusion visit

• Subject with dry skin according to the investigator assessment

• Subject with a pruritus intensity (on average over the previous 24 hours) ≥ 3 on a Numerical Rating Scale (NRS) between 0 and 10 (with 0 = no pruritus and 10 = worst imaginable pruritus) on the body\*

⁃ the head is not included in the evaluated area

Locations
Other Locations
Poland
Dermscan Poland
RECRUITING
Gdansk
Contact Information
Primary
Adeline Bacquey
adeline.bacquey@pierre-fabre.com
+33562877753
Backup
Christophe Chamard
christophe.chamard@pierre-fabre.com
+33562488566
Time Frame
Start Date: 2025-02-27
Estimated Completion Date: 2025-07-04
Participants
Target number of participants: 40
Treatments
Experimental: Adults with stable mild plaque psoriasis, dry skin and pruritus
Device: Dexeryl (RL3020-DP0364) Tested product is applied twice a day. The maximum duration of application is 30 days.
Sponsors
Leads: Pierre Fabre Dermo Cosmetique

This content was sourced from clinicaltrials.gov